Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Mustang Bio Inc

MBIO ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$0.37

▲ +2.64%

Market Cap $2.73M · Vol 1.09K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$2.73M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

32.04

Momentum

Beta

2.20

vs Market

52W High

$1.49

75.23% below

52W Low

$0.35

4.71% above

Volume

1.09K

Avg 3.79K

P/B

0.75

Price-to-book

ROE

N/A

Return on equity

Free Float

91.98%

Public shares

Shariah Compliance8 STANDARDS

✗ Mustang Bio Inc (MBIO) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MBIO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.89%

-27.20%

-41.56%

-51.06%

YTD

-62.39%

-75.40%

-99.51%

-99.98%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-1,921,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-14.28% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.75
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	7.58M

Technical Indicators

50-Day SMA	$0.48
200-Day SMA	$0.69
RSI (14)	32.04
Beta	2.20
52-Week High	$1.49
52-Week Low	$0.35

Volume Today	1.09K
Avg Daily Volume (30D)	3.79K
Relative Volume	0.29x
Volatility (10D)	32.19
Volatility (30D)	57.90
Free Float	91.98%

Analyst Consensus

N/A

Current Price $0.37

Mean Target N/A

52W Low$0.35 52W High$1.49

Current

Target

$0.35 $1.49

Current Analyst target

· 0 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00FXTN439

ISINUS62818Q3020

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +2.69% ARGX.BR argenx SE +1.76% ARGX argenx SE +1.05% GMAB.CO Genmab A/S +29.06% GMAB Genmab A/S +28.25%

Company Profile

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs into potential cures for cancers and autoimmune diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. It is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. It has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors.